Drug Profile

ALTO 202

Alternative Names: ALTO-202

Latest Information Update: 30 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avalo Therapeutics
Developer Alto Neuroscience
Class Antidepressants; Anxiolytics; Small molecules
Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Sep 2024 Phase-I clinical trials in Major depressive disorder (PO) (Alto Neurosciences pipeline, September 2024)
10 Apr 2024 Discontinued - Phase-II for Depressive disorders in USA (PO) (ALTO Neuroscience pipeline, April 2024)
10 Apr 2024 Discontinued - Phase-II for Post-traumatic stress disorders in USA (PO) (ALTO Neuroscience pipeline, April 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com